The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis.
In this study, we evaluated the potential of the synthetic antimicrobial peptide KLKL(5)KLK to augment the immune response and protective efficacy of the combined DNA vaccine against Mycobacterium tuberculosis. We demonstrated that immunization of mice with a combined DNA vaccine/KLKL(5)KLK mixture resulted in significantly higher protection than that induced by the combined DNA vaccine alone or by the Bacillus Calmette-Guérin (BCG) vaccine after challenge with a virulent M. tuberculosis strain (p < 0.01). Detailed analysis of the immune response revealed that the combined DNA vaccine/KLKL(5)KLK mixture stimulated higher IL-12 secretion, resulted in significantly more CD4(+)/CD44(high) and CD8(+)/CD44(high) T-cell production (p < 0.01), elicited 1.5- to 1.8-fold higher interferon-gamma (IFN-gamma) production, and produced stronger antigen-specific cytotoxic T lymphocyte activity than the combined DNA vaccine alone. Further, 125 days after the final immunization, mice immunized with the combined DNA vaccine/KLKL(5)KLK mixture significantly outpaced their combined DNA vaccine-immunized counterparts regarding antigen-specific IFN-gamma-producing cell numbers (p < 0.05) and antigen-specific IgG titers, indicating that KLKL(5)KLK provides a stronger and longer Th1-associated immune response. Taken together, our results indicate that the synthetic peptide KLKL(5)KLK is a potent adjuvant that can enhance and prolong the immune response of the combined DNA vaccine against M. tuberculosis.
Li
Min
M
The National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing, People's Republic of China.
Yu
Da-Hai
DH
Cai
Hong
H
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D004195:Disease Models, Animal; D005434:Flow Cytometry; D005822:Genetic Vectors; D007109:Immunity; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D009842:Oligopeptides / Q000494:pharmacology*; D010957:Plasmids; D014376:Tuberculosis / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000627:therapeutic use*; D019444:Vaccines, DNA / Q000627:therapeutic use*; D022223:Vaccines, Subunit / Q000494:pharmacology*; D014614:Vaccines, Synthetic / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; C531381:lysyl-leucyl-lysyl-leucyl-leucyl-leucyl-leucyl-leucyl-lysyl-leucyl-lysine